Fairmount Funds Management LLC 13F holdings, Q3 2024
Holdings as of September 30, 2024 · filings on SEC EDGAR · latest filing →
Fairmount Funds Management LLC disclosed 15 US equity positions worth $1.2bn in its Q3 2024 13F filing. The largest position was AXSM at 17.2% of the reported book, followed by NUVALENT INC and APGE.
What did Fairmount Funds Management LLC own in Q3 2024? Top 15 positions
| # | Stock | Sector | Weight | Value | Shares | Δ shares | vs prior |
|---|---|---|---|---|---|---|---|
| 1 | AXSM AXSOME THERAPEUTICS INC | Healthcare | 17.2% | $212.1m | 2,360,077 | – | |
| 2 | NUVALENT INC | 14.0% | $172.6m | 1,687,064 | – | ||
| 3 | APGE APOGEE THERAPEUTICS INC | Healthcare | 9.8% | $120.3m | 2,048,647 | – | |
| 4 | SYRE SPYRE THERAPEUTICS INC | 9.6% | $118.2m | 4,018,101 | – | ||
| 5 | ELVN ENLIVEN THERAPEUTICS INC | Healthcare | 6.6% | $81.8m | 3,202,798 | – | |
| 6 | KINIKSA PHARMACEUTICALS INTL | 6.5% | $80.1m | 3,204,841 | – | ||
| 7 | ORKA ORUKA THERAPEUTICS INC | Healthcare | 6.4% | $78.7m | 3,211,922 | – | |
| 8 | VRDN VIRIDIAN THERAPEUTICS INC | Healthcare | 6.4% | $78.4m | 3,445,813 | – | |
| 9 | DNTH DIANTHUS THERAPEUTICS INC | Healthcare | 6.0% | $73.9m | 2,700,691 | – | |
| 10 | COGT COGENT BIOSCIENCES INC | Healthcare | 5.5% | $67.2m | 6,225,641 | – | |
| 11 | DAWNGBX DAY ONE BIOPHARMACEUTICALS INC | 3.5% | $43.2m | 3,103,448 | – | ||
| 12 | CATBUSD ASTRIA THERAPEUTICS INC | 3.2% | $39.1m | 3,554,129 | – | ||
| 13 | BCAX BICARA THERAPEUTICS INC | 2.7% | $32.7m | 1,284,169 | – | ||
| 14 | ZBIO ZENAS BIOPHARMA INC | 2.6% | $32.0m | 1,892,806 | – | ||
| 15 | BCYC BICYCLE THERAPEUTICS PLC | Healthcare | 0.2% | $2.8m | 123,538 | – |
Weights are shares of the reported long US equity book (options excluded). Values are as filed, normalised to whole dollars. Share changes compare against the immediately preceding filing only.